48 research outputs found

    RĂ©servoir extra-digestif d’entĂ©robactĂ©ries productrices de bĂȘtalactamase Ă  spectre Ă©largi chez des patients non infectĂ©s: Ă©tude Ă  partir d’une recherche systĂ©matique dans les urines et d’autres prĂ©lĂšvements Ă  visĂ©e diagnostique

    Get PDF
    Notre objectif Ă©tait d’étudier le rĂ©servoir extra-digestif d’entĂ©robactĂ©ries productrices de ÎČ-lactamases Ă  spectre Ă©largi (EBLSE) en les recherchant dans des prĂ©lĂšvements Ă  visĂ©e diagnostique (PVD) pour lesquels les colonies bactĂ©riennes isolĂ©es sur les milieux de cultures utilisĂ©s ne sont pas obligatoirement analysĂ©es (identification bactĂ©rienne et antibiogramme) en routine. Pendant une pĂ©riode de 5 semaines, des identifications et des antibiogrammes ont Ă©tĂ© rĂ©alisĂ©s de maniĂšre systĂ©matique pour les colonies correspondant Ă  des entĂ©robactĂ©ries isolĂ©es dans certains PVD comme les urines, les prĂ©lĂšvements respiratoires, et un groupe de prĂ©lĂšvements appelĂ© “divers”. Les prĂ©lĂšvements pour lesquels un antibiogramme a Ă©tĂ© rĂ©alisĂ© conformĂ©ment Ă  la pratique de routine du laboratoire ont Ă©tĂ© considĂ©rĂ©s comme infectĂ©s. Les prĂ©lĂšvements pour lesquels les entĂ©robactĂ©ries ont Ă©tĂ© recherchĂ©es et Ă©tudiĂ©es suivant le protocole de l’étude ont Ă©tĂ© considĂ©rĂ©s comme colonisĂ©s. Au cours de l’étude, 2 312 urines, 327 prĂ©lĂšvements respiratoires et 1 887 prĂ©lĂšvements divers ont Ă©tĂ© envoyĂ©s au laboratoire. Parmi les 114 urines colonisĂ©es par au moins une entĂ©robactĂ©rie, 13 (11,4 %) comportaient une EBLSE, alors que cette proportion Ă©tait de 5,1 % (35/682) dans les urines infectĂ©es (p < 0,01). Parmi les prĂ©lĂšvements respiratoires et divers, 3 EBLSE ont Ă©tĂ© isolĂ©es dans 55 prĂ©lĂšvements colonisĂ©s par au moins une entĂ©robactĂ©rie. Au total, la recherche systĂ©matique d’EBLSE dans les PVD a permis une augmentation de 27,7 % du nombre de patients identifiĂ©s comme porteurs de ces bactĂ©ries. D’autres Ă©tudes pourraient ĂȘtre utiles pour Ă©valuer l’intĂ©rĂȘt de mettre en place une telle stratĂ©gie comme alternative au dĂ©pistage rectal habituellement pratiquĂ©

    New neutron detector based on Micromegas technology for ADS projects

    Get PDF
    A new neutron detector based on Micromegas technology has been developed for the measurement of the simulated neutron spectrum in the ADS project. After the presentation of simulated neutron spectra obtained in the interaction of 140 MeV protons with the spallation target inside the TRIGA core, a full description of the new detector configuration is given. The advantage of this detector compared to conventional neutron flux detectors and the results obtained with the first prototype at the CELINA 14 MeV neutron source facility at CEA-Cadarache are presented. The future developments of operational Piccolo-Micromegas for fast neutron reactors are also described

    Measurement of the 14^{14}N(n,p)14^{14}C cross section at the CERN n_TOF facility from sub-thermal energy to 800 keV

    Full text link
    Background: The 14^{14}N(n,p)14^{14}C reaction is of interest in neutron capture therapy, where nitrogen-related dose is the main component due to low-energy neutrons, and in astrophysics, where 14N acts as a neutron poison in the s-process. Several discrepancies remain between the existing data obtained in partial energy ranges: thermal energy, keV region and resonance region. Purpose: Measuring the 14N(n,p)14C cross section from thermal to the resonance region in a single measurement for the first time, including characterization of the first resonances, and providing calculations of Maxwellian averaged cross sections (MACS). Method: Time-of-flight technique. Experimental Area 2 (EAR-2) of the neutron time-of-flight (n_TOF) facility at CERN. 10^{10}B(n,α{\alpha})7^7Li and 235^{235}U(n,f) reactions as references. Two detection systems running simultaneously, one on-beam and another off-beam. Description of the resonances with the R-matrix code sammy. Results: The cross section has been measured from sub-thermal energy to 800 keV resolving the two first resonances (at 492.7 and 644 keV). A thermal cross-section (1.809±\pm0.045 b) lower than the two most recent measurements by slightly more than one standard deviation, but in line with the ENDF/B-VIII.0 and JEFF-3.3 evaluations has been obtained. A 1/v energy dependence of the cross section has been confirmed up to tens of keV neutron energy. The low energy tail of the first resonance at 492.7 keV is lower than suggested by evaluated values, while the overall resonance strength agrees with evaluations. Conclusions: Our measurement has allowed to determine the 14^{14}N(n,p) cross-section over a wide energy range for the first time. We have obtained cross-sections with high accuracy (2.5 %) from sub-thermal energy to 800 keV and used these data to calculate the MACS for kT = 5 to kT = 100 keV.Comment: 18 pages, 15 figures, 4 table

    Neutron capture cross section measurements of Am-241 at the n_TOF facility

    Get PDF
    Neutron capture on Am-241 plays an important role in the nuclear energy production and also provides valuable information for the improvement of nuclear models and the statistical interpretation of the nuclear properties. A new experiment to measure the Am-241(n,gamma) cross section in the thermal region and the first few resonances below 10 eV has been carried out at EAR2 of the n_TOF facility at CERN. Three neutron-insensitive C6D6 detectors have been used to measure the neutron-capture gamma cascade as a function of the neutron time of flight, and then deduce the neutron capture yield. Preliminary results will be presented and compared with previously obtained results at the same facility in EAR1. In EAR1 the gamma-ray background at thermal energies was about 90% of the signal while in EAR2 is up to a 25 factor much more favorable signal to noise ratio. We also extended the low energy limit down to subthermal energies. This measurement will allow a comparison with neutron capture measurements conducted at reactors and using a different experimental technique

    Measurements of the capture cross sections of natural silver in the resonance range with the time of flight technique

    Full text link
    Neutron capture cross section measurements have been performed at the time-of-flight facility GELINA of the EC-JRC-Geel. Prompt gamma rays, originating from a natural silver sample, were detected by a pair of C6D6 liquid scintillation detectors. The total energy detection principle in combination with the pulse height weighting technique has been used. In this contribution the experimental details together with the data reduction process are described. In addition, first results of calculations with REFIT are presented to verify the quality of recommended cross section data in the resolved resonance region

    Considerations sur les aires de répartition des campanules pyrénéennes à feuilles rondes

    No full text

    Considerations sur les aires de répartition des campanules pyrénéennes à feuilles rondes

    No full text

    Thermal neutron activation experiments on Ag, In, Cs, Eu, V, Mo, Zn, Sn and Zr in the MINERVE facility

    No full text
    International audienceThe MAESTRO experimental program has been designed to improve nuclear data uncertainty on a large range of materials used for detection, absorption, moderation and structures in LWRs. It consists of pile-oscillation and neutron activation experiments, carried out in the MINERVE low power facility. For this program, the core configuration has been designed to be representative of HZP (Hot Zero Power) conditions of a typical PWR. Samples of high purity elements have been manufactured with severe technological constraints to reach a target accuracy of ±\pm2% (1σ\sigma) on the measurement. This paper presents a preliminary analysis of activation experiments, based on TRIPOLI4 Monte-Carlo calculations and various nuclear data libraries

    New therapies for patients with multiple endocrine neoplasia type 1

    No full text
    In 1953, for the first time, Paul Wermer described a family presenting endocrine gland neoplasms over several generations. The transmission was autosomal dominant and the penetrance was high. Forty years later in 1997, the multiple endocrine neoplasia type 1 (MEN1) gene was sequenced, thus enabling diagnosis and early optimal treatment. Patients carrying the MEN1 gene present endocrine but also non-endocrine tumors. Parathyroid, pancreatic and pituitary impairment are the three main types of endocrine involvement. The present article details therapeutic management of hyperparathyroidism, neuroendocrine pancreatic tumors and pituitary adenomas in patients carrying the MEN1 gene. Significant therapeutic progress has in fact been made in the last few years. As concerns the parathyroid glands, screening of family members and regular monitoring of affected subjects now raise the question of early management of parathyroid lesions and optimal timing of parathyroid surgery. As concerns the duodenum-pancreas, proton-pump inhibitors are able to control gastrin-secreting syndrome, reducing mortality in MEN1 patients. Mortality in MEN1 patients is no longer mainly secondary to uncontrolled hormonal secretion but to metastatic (mainly pancreatic) disease progression. Tumor risk requires regular monitoring of morphological assessment, leading to iterative pancreatic surgery in a large number of patients. Finally, pituitary adenomas in MEN1 patients are traditionally described as aggressive, invasive and resistant to medical treatment. However, regular pituitary screening showed them to be in fact infra-centimetric and non-secreting in the majority of patients. Consequently, it is necessary to regularly monitor MEN1 patients, with regular clinical, biological and morphological work-up. Several studies showed that this regular monitoring impairs quality of life. Building a relationship of trust between patients and care provider is therefore essential. It enables the patient to be referred for psychological or psychiatric care in difficult times, providing long-term support and preventing any breakdown in continuity of care. (C) 2021 Elsevier Masson SAS. All rights reserved.Paroxysmal Cerebral Disorder
    corecore